- Home
- MCW vs ZLAB Comparison
MCW vs ZLAB Comparison
Compare MCW & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCW | ZLAB |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MCW | ZLAB |
|---|---|---|
| Price | $6.99 | $20.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $7.70 | ★ $51.52 |
| AVG Volume (30 Days) | ★ 1.1M | 745.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.86 | $19.06 |
| Revenue Next Year | $6.87 | $18.58 |
| P/E Ratio | $22.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.61 | $15.96 |
| 52 Week High | $8.60 | $44.34 |
Technical Indicators
Market Signals| Indicator | MCW | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 74.99 | 64.17 |
| Support Level | $5.77 | $19.50 |
| Resistance Level | $6.24 | $20.22 |
| Average True Range (ATR) | 0.20 | 0.74 |
| MACD | 0.08 | 0.36 |
| Stochastic Oscillator | 99.10 | 97.44 |
Price Performance
Historical ComparisonAbout MCW Mister Car Wash Inc.
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. Express Exterior Locations offers express exterior cleaning services and Interior Cleaning Locations offers both express exterior and interior cleaning services. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.